Silk Road Medical Q1 2024 revenue $48.5M (+21% YoY); net loss narrows to $14.1M

Silk Road Medical Inc

2024-Q1 EPS reported -$0.36 revenue$48,484,000

Revenue $48.5M, up 21% YoY driven by increased TCAR adoption.
Gross margin 75%, up from 69% YoY due to favorable production variances.
Net loss $14.1M ($0.36/share) vs $16.5M ($0.43/share) in Q1 2023.
Adjusted EBITDA loss improved to $3.9M from $7.4M in Q1 2023.
CEO cites commercial progress and steps toward sustainable profitability.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Silk Road Medical Inc reported the three months ended March 31, 2024 results: revenue $48.5 million, EPS $0.36 per share.

Period: the three months ended March 31, 2024
Revenue: $48.5 million
EPS: $0.36 per share
Result: preliminary results

Exact text from the filing

and patients and in our opportunity to drive strong, sustainable growth as a business.” First Quarter 2024 Financial Results Revenue for the first quarter of 2024 was $48.5 million, an increase of $8.4 million or 21%, compared to the first quarter of 2023. Growth was driven primarily by increased TCAR adoption. Gross profit for the first quarter of 2024

View on SEC.gov

Browse all earnings releases →

Source: SEC EDGAR

accession 0001397702-24-000029

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.